188869-05-8

Basic information

• Product Name: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 3-BROMO-4-OXOPIPERIDINE-1-CARBOXYLATE;3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;BUTTPARK 153\57-01;N-BOC-3-BROMO-4-OXOPIPERIDINE;1-Boc-3-bromo-4-oxopiperidine;1-Piperidinecarboxylic acid, 3-bromo-4-oxo-, 1,1-dimethylethyl ester;1-tert-Butoxycarbonyl-3-bromo-4-oxopiperidine;1-tert-Butyloxycarbonyl-3-bromo-4-oxopiperidine
• CAS NO: 188869-05-8
• Molecular Formula: C₁₀H₁₆BrNO₃
• Molecular Weight: 278.14
• EINECS: 1592732-453-0
• Mol File: 188869-05-8.mol

Chemical Properties

• Boiling Point: 333.3 °C at 760 mmHg
• Flash Point: 155.4 °C
• Appearance: Light yellow solid
• Density: 1.422 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: 2-8°C(protect from light)
• PKA: -3.35±0.40(Predicted)
• CAS DataBase Reference: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(188869-05-8)
• EPA Substance Registry System: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(188869-05-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 188869-05-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-4-oxo-piperidine-1-carboxylic acid tert-butyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, 3-Bromo-4-oxo-piperidine-1-carboxylic acid tert-butyl ester is utilized as a building block for the creation of new agrochemicals. Its versatility in chemical reactions enables the production of compounds with targeted effects on pests and diseases, thereby enhancing crop protection and yield.
Used in Research and Development:
3-Bromo-4-oxo-piperidine-1-carboxylic acid tert-butyl ester is also employed in research and development settings. It serves as a valuable tool for scientists to explore new chemical reactions and pathways, potentially leading to the discovery of novel therapeutic agents and agrochemicals.

InChI:InChI=1/C10H16BrNO3/c1-10(2,3)15-9(14)12-5-4-8(13)7(11)6-12/h7H,4-6H2,1-3H3

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 118652-88-3 3-bromo-piperidin-4-one-hydrobromide 
• 41979-39-9 4-piperidone hydrochloride 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 165948-24-3 5-tert-Butoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridine 
• 165948-23-2 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 1522362-17-9 tert-butyl 3-(2-(4-(tert-butyl)phenyl)-2-oxoethyl)-4-oxopiperidine-1-carboxylate 
• 1174737-79-1 tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydro[1,3]thiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 365996-06-1 2-Bromo-5-tert-butoxycarbonyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine 
• 365996-05-0 tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 913731-92-7 tert-butyl 2-(2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-(2,5-difluorophenyl)-2-phenyl-1,3,4-thiadiazol-3(2H)-yl)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 1186205-63-9 tert-butyl 2-[4-(3-chloropropoxy)phenyl]-7a-hydroxy-3a,6,7,7a-tetrahydro[1,3]thiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 1004764-02-6 2-{4-[(3-chloropropyl)oxy]phenyl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine 
• 1004527-72-3 2-phenyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine hydrobromide 
• 325486-45-1 tert-butyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 

Relevant articles and documents

1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (Ki=4.0 nM) H3R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half-life in both rats and dogs. It has demonstrated high receptor occupancy (ED80=0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub-therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton’ s tyrosine kinase (Btk), and for treating disorders mediated thereby.

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and th